Patients' perceptions, attitudes, and experiences about the management of mild-to-moderate ulcerative colitis

被引:14
|
作者
Casellas, Francesc [1 ]
Vicens, Daniel Ginard [2 ]
Riestra Menendez, Sabino [3 ]
Alfaro Oliver, Noelia [4 ]
机构
[1] Hosp Univ Vall dHebron, Ciberehd, Crohn Colitis Care Unit, Barcelona 08035, Spain
[2] Hosp Univ Son Espases, Dept Gastroenterol, Palma de Mallorca 07120, Islas Baleares, Spain
[3] Hosp Univ Cent Asturias, Dept Gastroenterol, Oviedo 33006, Asturias, Spain
[4] Adv Res Tech Hlth Serv TAISS, Madrid 28034, Spain
关键词
Ulcerative colitis; Management of the disease; Treatment of the disease; Quality of life; Patient satisfaction; INFLAMMATORY-BOWEL-DISEASE; HEALTH-CARE; SATISFACTION; PERSPECTIVE; COPENHAGEN;
D O I
10.1016/j.crohns.2014.02.013
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective: To establish the perceptions, attitudes, experiences, and satisfaction with clinical management of ulcerative colitis (UC) patients, particularly in aspects related to treatment. Methods: A qualitative, descriptive, exploratory study. A discussion group was performed in patients who were in remission according to the criteria of the Mayo index, who had never taken biologics or corticosteroids in the past year. They were selected by: course (mild/moderate), time since onset (under 5 years/5 to 9 years/10 years or more), follow-up area (primary care [PC]-hospital/PC-specialist care/hospital), treatment (yes/no), UC care unit (yes/no), belongs to patient associations (yes/no) and sex. A descriptive-interpretative content analysis was performed to detect emerging categories, providing them with an explanatory framework. Results: Diagnostic delay was detected due to lack of clinical suspicion from PC and delayed diagnostic tests. For follow-up, patients prefer care on demand, channeled through remote care, which helps to resolve questions, problems with treatment, or when a relapse occurs, minimizing visits to the hospital. They demand more information, both about UC and treatment. The expectations about treatments are limited, so they mainly requested efficacy and safety. Conclusion: The results suggest the importance of developing strategies to facilitate care on demand and remote care, and to investigate on effective and safe treatments to minimize the detriment to quality of life of patients. These strategies should guarantee fast care and, together with safe and effective treatments, optimize the management of UC patients. (C) 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1097 / 1107
页数:11
相关论文
共 50 条
  • [31] The Effect of Vitamin D on Serum Asymmetric Dimethylarginine in Patients with Mild to Moderate Ulcerative Colitis
    Hosseinzadeh-Attar, Mohammad Javad
    Sharifi, Amrollah
    Nedjat, Saharnaz
    Mohamadkhani, Ashraf
    Vahedi, Homayoon
    INTERNATIONAL JOURNAL FOR VITAMIN AND NUTRITION RESEARCH, 2020, 90 (1-2) : 17 - 22
  • [32] Tripeptide K(D)PT Is Well Tolerated in Mild-to-moderate Ulcerative Colitis: Results from a Randomized Multicenter Study
    Kucharzik, Torsten
    Lemmnitz, Gunter
    Abels, Christoph
    Maaser, Christian
    INFLAMMATORY BOWEL DISEASES, 2017, 23 (02) : 261 - 271
  • [33] Combined Diosmectite and Mesalazine Treatment for Mild-to-Moderate Ulcerative Colitis: A Randomized, Placebo-Controlled Study
    Jiang, Xue-Liang
    Wang, Hua-Hong
    Cui, Hui-Fei
    MEDICAL SCIENCE MONITOR, 2015, 21 : 163 - 170
  • [34] Consensus document on the management preferences of patients with ulcerative colitis: points to consider and recommendations
    Casellas, Francesc
    Guinard Vicens, Daniel
    Garcia-Lopez, Santiago
    Gonzalez-Lama, Yago
    Arguelles-Arias, Federico
    Barreiro-de Acosta, Manuel
    Marin Sanchez, Laura
    Manuel Mendive, Juan
    Saldana, Roberto
    Cabez, Ana
    Gomez, Susana
    Loza, Estibaliz
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2020, 32 (12) : 1514 - 1522
  • [35] MMX® Mesalazine A Review of its Use in the Management of Mild to Moderate Ulcerative Colitis
    Yang, Lily P. H.
    McCormack, Paul L.
    DRUGS, 2011, 71 (02) : 221 - 235
  • [36] Possible genetical predictors of efficacy and safety of budesonide-MMX in patients with mild-to-moderate ulcerative colitis, and safety comparison with methylprednisolone
    Resal, Tamas
    Mango, Katalin
    Bacsur, Peter
    Szanto, Kata
    Pigniczki, Daniella
    Keresztes, Csilla
    Rutka, Mariann
    Balint, Anita
    Milassin, Agnes
    Bor, Renata
    Fabian, Anna
    Szepes, Zoltan
    Farkas, Klaudia
    Monostory, Katalin
    Molnar, Tamas
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (06) : 517 - 524
  • [37] Natural History and Longitudinal Outcomes of Patients with Mild-to-Moderate Ulcerative Proctitis or Ulcerative Proctosigmoiditis: A Single-Center, Retrospective Study
    Ye, Kexin
    Jin, Zhenhe
    Chen, Qichen
    Cen, Li
    Pan, Jiaqi
    Zhou, Tianyu
    Jiang, Wenxi
    Liu, Zhaoxue
    Luo, Linwen
    Shen, Zhe
    DIGESTIVE DISEASES AND SCIENCES, 2024, 69 (10) : 3701 - 3709
  • [38] MMX® MesalazineA Review of its Use in the Management of Mild to Moderate Ulcerative Colitis
    Lily P. H. Yang
    Paul L. McCormack
    Drugs, 2011, 71 : 221 - 235
  • [39] Mild to moderate ulcerative colitis: sequential and combined treatments
    Coelho, J.
    Marteau, P.
    INTESTINAL DISORDERS, 2009, 164 : 103 - 106
  • [40] Treatment Algorithm for Mild and Moderate-to-Severe Ulcerative Colitis: An Update
    Burri, Emanuel
    Maillard, Michel H.
    Schoepfer, Alain M.
    Seibold, Frank
    Van Assche, Gert
    Riviere, Pauline
    Laharie, David
    Manz, Michael
    DIGESTION, 2020, 101 (SUPPL 1) : 2 - 15